Patents by Inventor Tamar Yechezkel
Tamar Yechezkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9119885Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy.Type: GrantFiled: February 7, 2014Date of Patent: September 1, 2015Assignee: Steba Biotech S.A.Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
-
Publication number: 20140154181Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radioimaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for targeted chemotherapy.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: STEBA BIOTECH S.A.Inventors: Doron EREN, Tamar YECHEZKEL, Yoseph SALITRA, Natalia KOUDINOVA
-
Patent number: 8673270Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy.Type: GrantFiled: October 22, 2009Date of Patent: March 18, 2014Assignee: Steba Biotech S.A.Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
-
Publication number: 20110250144Abstract: The invention provides RGD-containing cyclic peptidomimetics; conjugates of said peptidomimetics and a moiety of a payload selected from fluorescent probes, photosensitizers, chelating agents, or cytotoxic agents; and pharmaceutical compositions comprising these conjugates. The conjugates of the invention are useful both for diagnostic purposes and treatment of various diseases, disorders and conditions. More specifically, conjugates comprising fluorescent probes can be used for diagnostic purposes, e.g., visualization of organs and tissues, and diagnosis of tumors; conjugates comprising photosensitizers can be used for photodynamic therapy of both tumors and nonneoplastic tissues; conjugates comprising chelating agents can be used in radio imaging or radiotherapy; and conjugates comprising cytotoxic agents can be used for in targeted chemotherapy.Type: ApplicationFiled: October 22, 2009Publication date: October 13, 2011Applicant: STEBA BIOTECH N.V.Inventors: Doron Eren, Tamar Yechezkel, Yoseph Salitra, Natalia Koudinova
-
Patent number: 7700717Abstract: Novel photo-active labeled diagnostic and therapeutic peptides which are conformationally constrained backbone cyclized somatostatin analogs, having improved somatostatin receptor subtype affinity and selectivity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as chemical and metabolic stability, selectivity, increased bioavailability and improved pharmacokinetics. Furthermore, the unique patterns of receptor subtype selectivity provide compounds having improved diagnostic and therapeutic utilities. Pharmaceutical compositions comprising the photo-active backbone cyclized somatostatin analogs, reagents for synthesizing same, and methods of using such compositions for diagnostic and therapeutic purposes including optical imaging and photodynamic therapy are also disclosed.Type: GrantFiled: September 24, 2004Date of Patent: April 20, 2010Assignee: DeveloGen Israel Ltd.Inventors: Thomas A. Bonasera, Nurit Livnah, Yoseph Salitra, Tamar Yechezkel
-
Publication number: 20090156507Abstract: The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a linker or a spacer. The complex molecules are preferably peptide conjugates having improved cell-permeability, serum stability and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed.Type: ApplicationFiled: August 22, 2008Publication date: June 18, 2009Inventors: Narit Livnah, Alexander Levitzki, Hanoch Senderovitz, Tamar Yechezkel, Yosef Salitra, Pninit Litman, Osnat Ohne
-
Patent number: 7407939Abstract: The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.Type: GrantFiled: January 23, 2004Date of Patent: August 5, 2008Assignee: CureGenics Ltd.Inventors: Nurit Livnah, Tamar Yechezkel, Yosef Salitra, Boris Perlmutter, Onsat Ohne, Ilana Cohen, Pninit Litman, Hanoch Senderowitz
-
Publication number: 20080070843Abstract: The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.Type: ApplicationFiled: September 27, 2007Publication date: March 20, 2008Inventors: Nurit Livnah, Tamar Yechezkel, Yosef Salitra, Boris Perlmutter, Onsat Ohne, Ilana Cohen
-
Publication number: 20070078092Abstract: The present invention provides inhibitors of protein kinases comprising a molecule having at least a first moiety competent for penetration of the molecule into cells, and a second moiety for having a protein kinase inhibiting effect within the cells. The first moiety is joined to the second moiety through a linker or a spacer. The complex molecules are preferably peptide conjugates having improved cell-permeability, serum stability and kinase selectivity compared to known protein kinase inhibitors. Pharmaceutical compositions that include these protein kinase inhibitors, and methods of using such compositions for treatment of cancers and other diseases associated with protein kinase activity are also disclosed.Type: ApplicationFiled: December 6, 2005Publication date: April 5, 2007Inventors: Nurit Livnah, Alexander Levitzki, Hanoch Senderovitz, Tamar Yechezkel, Yosef Salitra, Pninit Litman, Osnat Ohne
-
Patent number: 7045592Abstract: A process is disclosed for using bis-(trichloromethyl)carbonate (triphosgene), diphosgene or phosgene as efficient and effective coupling reagents during coupling of carbohydrates to peptide chains. This process is particularly useful for the coupling to sterically hindered amino acid residues, or for other difficult couplings. The reagents can be used for the derivatization of peptides by formation of a bond between a free amine on a peptide and a carbohydrate.Type: GrantFiled: December 18, 2002Date of Patent: May 16, 2006Assignee: DeveloGen Israel Ltd.Inventors: Eliezer Falb, Tamar Yechezkel, Yoseph Salitra
-
Publication number: 20050090429Abstract: Novel photo-active labeled diagnostic and therapeutic peptides which are conformationally constrained backbone cyclized somatostatin analogs, having improved somatostatin receptor subtype affinity and selectivity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as chemical and metabolic stability, selectivity, increased bioavailability and improved pharmacokinetics. Furthermore, the unique patterns of receptor subtype selectivity provide compounds having improved diagnostic and therapeutic utilities. Pharmaceutical compositions comprising the photo-active backbone cyclized somatostatin analogs, reagents for synthesizing same, and methods of using such compositions for diagnostic and therapeutic purposes including optical imaging and photodynamic therapy are also disclosed.Type: ApplicationFiled: September 24, 2004Publication date: April 28, 2005Inventors: Thomas Bonasera, Nurit Livnah, Yoseph Salitra, Tamar Yechezkel
-
Publication number: 20050026840Abstract: The present invention provides small molecules having high affinity to the ATP binding site of protein kinases, which are conjugated to apeptide or peptidomimetic moiety which mimics the substrate of PKB. The chimeric compounds according to the present invention preferably serve as PKB inhibitors with improved activity and selectivity. Novel ATP mimetic compounds, particularly isoquinoline derivatives, conjugated with peptides or peptidomimetics are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune disease, are disclosed.Type: ApplicationFiled: January 23, 2004Publication date: February 3, 2005Inventors: Nurit Livnah, Tamar Yechezkel, Yosef Salitra, Boris Perlmutter, Onsat Ohne, Ilana Cohen, Pninit Litman, Hanoch Senderowitz
-
Publication number: 20040102364Abstract: Novel radiodiagnostic and radiotherapeutic peptides which are conformationally constrained backbone cyclized somatostatin analogs, having improved somatostatin receptor subtype affinity and selectivity are disclosed. The backbone cyclized peptide analogs disclosed possess unique and superior properties over other analogs, such as chemical and metabolic stability, selectivity, increased bioavailability and improved pharmacokinetics. Furthermore, the unique patterns of receptor subtype selectivity provide compounds having improved diagnostic and therapeutic utilities. Pharmaceutical compositions comprising the backbone cyclized somatostatin analogs and radiolabelled analogs, reagents for synthesizing same, and methods of using such compositions for radiodiagnostic and radiotherapeutic purposes are also disclosed.Type: ApplicationFiled: August 4, 2003Publication date: May 27, 2004Inventors: Thomas A. Bonasera, Nurit Livnah, Tamar Yechezkel, Yoseph Salitra
-
Publication number: 20030195331Abstract: A process is disclosed for using triphosgene as an efficient and effective coupling reagent during peptide synthesis, by in situ generation of amino acid chloride from a protected amino acid. This process is particularly useful for the coupling to sterically hindered amino acid residues, or for other difficult couplings. Furthermore, the same reagent can be used for the derivatization of peptides by formation of an amide bond between a free amine on a peptide and a carboxylic acid, or for the coupling of an amino acid to a solid support.Type: ApplicationFiled: December 18, 2002Publication date: October 16, 2003Applicant: PEPTOR LTD.Inventors: Eliezer Palb, Tamar Yechezkel, Yoseph Salitra
-
Patent number: 6512092Abstract: A process is disclosed for using triphosgene as an efficient and effective coupling reagent during peptide synthesis, by in situ generation of amino acid chloride from a protected amino acid. This process is particularly useful for the coupling to sterically hindered amino acid residues, or for other difficult couplings. Furthermore, the same reagent can be used for the derivatization of peptides by formation of an amide bond between a free amine on a peptide and a carboxylic acid, or for the coupling of an amino acid to a solid support.Type: GrantFiled: January 9, 2001Date of Patent: January 28, 2003Assignee: Peptor Ltd.Inventors: Eliezer Falb, Tamar Yechezkel, Yoseph Salitra
-
Publication number: 20010007037Abstract: A process is disclosed for using triphosgene as an efficient and effective coupling reagent during peptide synthesis, by in situ generation of amino acid chloride from a protected amino acid. This process is particularly useful for the coupling to sterically hindered amino acid residues, or for other difficult couplings. Furthermore, the same reagent can be used for the derivatization of peptides by formation of an amide bond between a free amine on a peptide and a carboxylic acid, or for the coupling of an amino acid to a solid support.Type: ApplicationFiled: January 9, 2001Publication date: July 5, 2001Inventors: Eliezer Falb, Tamar Yechezkel, Yoseph Salitra